Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma

References

• Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing ICS. Lancet 1994;344:219–24
   PubMed Web of Science ®Google Scholar
• Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481–8
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl C-G, Postma DS, Tattersfield AE, O’Byrne PM, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405–11
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392–7
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. National Institutes of Health: National Heart, Lung, and Blood Institute. Bethesda, MD: National Institutes of Health; 2002 (publication No. NIH-NHLI 02–3659)
   Google Scholar
• British Thoracic Society (BTS)/Scottish Intercollegiate Guideline Network (SIGN). British Guideline on the management of asthma. Thorax 2003;58(Suppl. 1):1–94
   Google Scholar
• Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights in Europe (AIRE) study. Eur Respir J 2000;16:802–7
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002;19:182–91
   PubMed Web of Science ®Google Scholar
• Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000;117:440–6
   PubMed Web of Science ®Google Scholar
• Charlton I, Charlton G, Broomfield J, Mullee MA. Evaluation of peak flow and symptoms only self management plans for control of asthma in general practice. BMJ 1990;301:1355–9
   PubMed Web of Science ®Google Scholar
• Lahdensuo A, Haahtela T, Herrala J, Kava T, Kiviranta K, Kuusisto P, Peramaki E, Poussa T, Saarelainen S, Svahn T. Randomised comparison of guided self-management and traditional treatment of asthma over one year. BMJ 1996;312:748–52
   PubMed Web of Science ®Google Scholar
• Liljas B, Lahdensuo A. Is asthma self-management cost-effective? Patient Educ Couns 1997;32\(Suppl. 1):S97–S104
   PubMedGoogle Scholar
• Lahdensuo A, Haahtela T, Herrala J, Kava T, Kiviranta K, Kuusisto P, Pekurinen M, Peramaki E, Saarelainen S, Svahn T, Liljas B. Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland. BMJ 1998;316:1138–9
   PubMed Web of Science ®Google Scholar
• Gibson PG, Coughlan J, Wilson AJ, Abramson M, Bauman A, Hensley MJ, Walters EH. Self-management education and regular practitioner review for adults with asthma (Cochrane review). In: The Cochrane Library, Issue 4. Oxford: The Cochrane Library; 2003
   Google Scholar
• National Asthma Campaign. Out in the open. A true picture of asthma in the United Kingdom today. Asthma J 2001;6(Suppl.):1–16
   Google Scholar
• Haughney J, Barnes G, Partridge M. Living and breathing – a national survey of patients’ views of asthma and its treatment. Thorax 2001;56(Suppl. III):S51
   Google Scholar
• Palmqvist M, Ibsen T, Mellén A, Lötvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999;160:244–9
   PubMed Web of Science ®Google Scholar
• British National Formulary. London: British Medical Association, Royal Pharmaceutical Society of Great Britain; 2003
   Google Scholar
• Ställberg B, Olsson P, Jörgensen LA, Lindarck N, Ekström T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003;57:656–61
   PubMed Web of Science ®Google Scholar
• FitzGerald MJ, Sears MR, Boulet L-P, Becker AB, McIvor AR, Ernst P, Smiljanic-Georgijev NM, Lee JSM. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing. A 5-month multicentre Canadian study. Can Respir J 2003;10 (in press)
   Google Scholar
• Olsson P, Karlsson G, Ekström T, Lindarck N. Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen. Eur Respir J 2003;22\(Suppl. 45):411s [Abstract No. P2643]
   Google Scholar
• American Thoracic Society (ATS). Standards for the diagnosis and care of patients with chronic obstructive airway disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225–44
   PubMed Web of Science ®Google Scholar
• Quanjer PhH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. Report of the Working Party: Standardisation of lung function tests. European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J 1993;6(Suppl. 16):5–40
   Google Scholar
• Bateman ED, Bousquet J, Braunstein GL. Is overall asthma control being achieved? A hypothesis-generating study. Eur Respir J 2001;17:589–95
   PubMed Web of Science ®Google Scholar
• Ringdal N, Chuchalin A, Chovan L, Tudoric N, Maggi E, Whitehead PJ. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide™ (50/250 μg bd Diskus™ versus formoterol (12 μg bd) and budesonide (800 μg bd) given concurrently (both via Turbuhaler™) in patients with moderate-to-severe asthma. Respir Med 2002;96:851–61
   PubMed Web of Science ®Google Scholar
• Zetterström O, Buhl R, Mellem H, Perpiñá M, Hedman J, O’Neill S. Symbicort® (budesonide and formoterol in a single inhaler) improves asthma control in adults: a randomised controlled study. Eur Respir J 2001;18:262–8
   PubMed Web of Science ®Google Scholar
• Chapman KR, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Briggs M. Salmeterol and fluticasone propionate (50/250 μg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999;6:45–51
   PubMedGoogle Scholar
• Hjelmgren J, Berggren F, Andersson F. Health economic guidelines – similarities, differences and some implications. Values Health 2001;4:225–50
   PubMedGoogle Scholar
• van der Palen J, Klein JJ, van Herwaarden CLA, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J 1999;14:1034–7
   PubMed Web of Science ®Google Scholar
• Gustafsson D, Olsson P, Ställberg B, Ekström T, Lindarck N. Budesonide/formoterol adjustable maintenance dosing and fixed dosing in adolescents with asthma: a Swedish study. Eur Respir J 2003;22(Suppl. 45):258s [Abstract No. P1697]
   Google Scholar
• Leuppi JD, Salzberg M, Meyer L, Bucher SE, Nief M, Brutsche MH, Tamm M. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss Med Wkly 2003;133:302–9
   PubMed Web of Science ®Google Scholar
• Moretti AM, Canonica GW, Sanguinetti CM, Mangrella M, Stabilini M, and the CAST Study Team. Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study. Eur Respir J 2003;22(Suppl. 45):259s [Abstract No. P1703]
   Google Scholar
• Sears MR, McOvor A, Becker A, Fitzgerald JM, Boulet LP, Ernst P, Goergijev NS, Lee J. Budesonide/formoterol adjustable maintenance dosing effectively improves asthma symptom severity: a multicentre Canadian study. Eur Respir J 2003;22(Suppl. 45):258s [Abstract No. P1695]
   PubMedGoogle Scholar
• FitzGerald JM, Becker A, Chung K, Lee J. Randomised, controlled, multi-centre study to compare double-dose versus maintenance dose of inhaled corticosteroids (ICS) during asthma exacerbations. Am J Respir Crit Care Med 2000;161:A187
   PubMedGoogle Scholar
• van der Woude HJ, Boorsma M, Bergqvist PBF, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004 (in press)
   PubMed Web of Science ®Google Scholar
• Balanag VM, Yunus F, Yang P-C, Jorup C. Budesonide/formoterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents. Eur Respir J 2003;22(Suppl. 45):445s [Abstract No. P2836]
   Google Scholar